17 research outputs found

    Low incidence of SARS-CoV-2, risk factors of mortality and the course of illness in the French national cohort of dialysis patients

    Get PDF

    Induction of CD4(+)CD25(+) regulatory T cells by copolymer-I through activation of transcription factor Foxp3

    No full text
    Copolymer-I (COP-I) has unique immune regulatory properties and is a treatment option for multiple sclerosis (MS). This study revealed that COP-I induced the conversion of peripheral CD4(+)CD25(-) to CD4(+)CD25(+) regulatory T cells through the activation of transcription factor Foxp3. COP-I treatment led to a significant increase in Foxp3 expression in CD4(+) T cells in MS patients whose Foxp3 expression was reduced at baseline. CD4(+)CD25(+) T cell lines generated by COP-I expressed high levels of Foxp3 that correlated with an increased regulatory potential. Furthermore, we demonstrated that the induction of Foxp3 in CD4(+) T cells by COP-I was mediated through its ability to produce IFN-γ and, to a lesser degree, TGF-β1, as shown by antibody blocking and direct cytokine induction of Foxp3 expression in T cells. It was evident that in vitro treatment and administration with COP-I significantly raised the level of Foxp3 expression in CD4(+) T cells and promoted conversion of CD4(+)CD25(+) regulatory T cells in wild-type B6 mice but not in IFN-γ knockout mice. This study provides evidence for the role and mechanism of action of COP-I in the induction of CD4(+)CD25(+) regulatory T cells in general and its relevance to the treatment of MS
    corecore